Member Info for pomander

Board Meeting 23rd March - http://www.regentpac.com/ICMServlet/download/13-2167-3533/EAnnt-NoticeofBoardMeeting(13Mar2018).pdf

Bignose- I have always believed that the HK and Macau launches were strategic - Macau is a gambling resort city and only has a poulation of 600,000, so that would equate to under 10,000 unit projected sales. HK although much larger sstill ion the bigger scheme of things a very small potential market. In a normal world the HK and Macau launches should have little SP impact because of this and because they should also be largely priced in having been announced. JG knew about the maven dsposal before the HKSE was eventually informed as the RP website was updated immediately as RP has to be comliant with HK listing requirements.

Intuitively I would suggest that Dapoxetines failure to gain any NHS traction in the UK has more to do with it being a very poor drug than anything else. Fortacin has never been promoted as seeking NHS endorsement, and for those regional health authorities that have looked at it, cost is the over -riding consideration. Makes far more sense to me to launch Fortacin in the UK on the back of success in other countries. Thanks SOTRR- will give that some thought but I think you have a good handle on things.

Yes indeed, and it does beg the question- ''what drove the huge wall of money that arrived post UK launch?''. Why so much interest then and as you say very little at the moment? Whilst some investors will wait for sales figures many if they like the story and view as even potentially a fraction as successful as the Viagra one, would normally want to get in much earlier. We are not seeing any sign of that. There has been no focus as yet on the UK market, no launch compaign and no money spent on promotion.I don't think there is any traction in sales as yet either. I suspect Recordati will focus on the E5 as you say and the UK will be launched by them later this year. Is anyone attending MasterInvestor on Friday ?

Not sure I would read too much into this. I supsect it is probably linked to Recordati taking over the show now and having a preferred alternative to Doctors 4 U. It was not that long ago that Doctors were waxing lyrical about what appeared to be very modest sales levels.

Piltick you are a sensible chap, even if the Mousetrap was proven to be commercially viable, which it is still a long way from being so, who is going to lend money against technology that has no protection ? I don't think you appreciate just how much capital this will require to fully develop . Phe has only ever raised money by Placings and distressed loans from Bond. It's settled many debts by iussuing shares, again unable to raise other forms of funding the business.

I suspect Phe must be running pretty low on cash and they will need plenty of that this year. With the share price sitting precariously around its nominal value I think they will instigate whatever they can to rectify this to be able to get a Placing away. As has been mentioned for some time this company is going to be hit with a Tsunami of shares leaving shareholders diluted to kingdom come.

Crusader82 Just to be clear, I have not asked Alq how Dr Mike did certain things or how he achieved certain numbers. Alq has offered his own numbers/views and I have questioned and debated them with him. I have not sought clarification on numbers from Alq, but his knowledge on how Pharma licences operate is very useful. As I said I feel able to filter and disregard certain information in his posts. His claims that RP simply inserted milestone triggers at absurdly high levels and likely wholly unachievable to bolster the headline numbers for PR purposes are disturbing and questions the integrity and honesty of all concerned. I don�t subscribe to this theory. Unfortunately Dr Mike�s presentation last year could have been better, but I have every confidence that he will put that right this year, big time. From an investment perspective the aggressive approach to achieve the big multiples is to be in, ahead of sales being announced. That would also likely be the approached adopted by a potential suitor who could simply write-off his investment if sales did not match expectations. Given recent announcements� and developments I find it most surprising that there has been so little share price action recently. It�s just a guess on identity based upon some comments in his posts .

No funding has been provided, they have not been exercised.

Morning Bignose- Whilst I fully appreciate that Alq�s choice of language rubs people up the wrong way and I am not deluded enough to fail to see that he has an axe to grind I nevertheless have no problems with him posting and expressing his views, however biased they may seem in places. I don�t suppose that I will ever find out the reasons for his obvious delight in rubbishing RP/PLE and all and sundry connected but quite frankly I could not care less. My best guess at this time is that Alq is a certain David Scott at C.E.L. forpharma. I am not a Pharma expert, he is, but that does mean he has a monopoly on being correct. I believe or at least hope that I am capable of dissecting his missives and taking from them information that is of use and totally disregarding the rest. The recent exchange, particularly in connection with the calculation of royalties I have found to be very useful. Unfortunately Dr Mike�s presentation https://www.youtube.com/watch?v=wCWd3LU-6Lk at the Master Investor show was not the best. He infers that royalties are calculated on gross retail sales and even says �� 15% of �300 m for x years is certainly worth having.�� I also note that starts out by apologising to investors for having to wait 2 years for this presentation because his fellow director doesn�t always turn up. Reading between the lines and in addition to Dr Mike not joining the RP Board I suspect there is some friction between JG and Dr Mike, although I may be completely off base. Dr Mike will again be at the Master Investor show on March 17th and I am confident all will become much clearer then. He is undoubtedly and achiever and to be respected. I look forward to seeing the video of his presentation. Without getting into detail on pricing, usage, wholesale price etc as it serves little meaningful purpose, the valuation report commissioned for the takeover of Ple projects circa 2 million users of Fortacin in the first year rising to 3.65 m by 2023. This is based upon a relevant adult population of 86 m and 9% market penetration rising to 17% in 2023. This approach also differs from the one adopted for the US market and i do find it odd that the projected market capture is actually lower in the US despite all forms of aggressive marketing campaigns (TV, SM , radio etc.) being available unlike in Europe. I see share volume down to a paltry 2m yesterday � certainly little or no following of RP in HK at the moment. This is odd given we are now on the cusp of generating revenues and in light of the volumes post UK launch.

Rather than allowing shareholders to speculate on why the Fuel Cell has not been delivered whu doesn't KA inform the market accordingly. If delivery has simply be delayed as some are suggesting, why has that not been announced and the new timetable presented ? There is a very fishy smell about how this company is being run- 30 m shares options for KA, 90 m in total at rock bottom proces - its taking the p-ss

In the absence of any update from KA I think we have to assume and take KA on his word that the reason for non delivery is that the AFC fuel cell is not compatible with the Mousetrap. There is a very common theme here developing, announcements of wonderful developments and then complete silence to follow on them. Why has KA suddenly upped his options from the 5m and 6 m previously granted to a whooping 30 m. Who is on the renumeration committee and does KA simply have carte blanche to grant options willy nilly ? Putting aside the technolgy which is another debate, there should beconcern about how this company is being run, we had positive announcements on Pyromex whilst Phe already knew customers were voicing concerns, we had the ReNewme fiasco, we had complete silence following the Brisbane demonstrations which were meant to generate orders, two Nomads have resigned and the auditors, the accounts and many of the announcements have been strewn with errors and we have a bunch of dodgy deals with connected parties including waste2tricity which in my book is a horrendous deal for shareholders. In the meantime Bond, an insider has cashed out at rock bottom prices whilst the directors line their own pockets with outrageous share grants.

Au contraire and might I suggest that you rrefer agin to teh RNs for you are inserting wpords and information that do not exist within its content. Suggesting that Phe waits to incorporate rapidly advancing fuel cell technology is twisted logic.In any event by that time Phe's technbology will most likely be obsolete anyway.

Alq- thks and that was always my understanding and I actually used a net profit basis calculation for my numbers which is even more conservative. The question is what an earth Dr Mike was doing referring to 15% to 25% of $232 m as being worth having when we know from the RP presentation that the $232 is in reference to Peak Annual Product Sales. � ie gross retail sales. It seems to be a schoolboy error and compounded by the fact that it was made at an investor conference of all places. I have not seen the original license agreement but the next � 5 is triggered by net sales of �100 m and the remaining �20m by reaching net sales of �450. Intuitively these does not make a great deal of sense to me as given Recordati�s current projections it would take between 18 and 23 years to trigger the final milestone payment. I looks to me that Recordati did indeed present much higher numbers and are dumbing down corporate expectations. �232m peak sales would equate very roughly to around �100m net sales.

Yes, dear old Glyn - I have also dared to severely criticise his corporate strategy which in my view has backed the company into a corner.

Alq - you stated that the net price for royalty purposes will be around Euro 35-45 which surprised me as I had always understood that the royalty was calculated on the retail sales price. Listening again to Mike Wyllie at the Master Investor he confirms my understanding. He actually says royalties will be between 15% and 25% and that anyone could work out what royalties are likely to come back into the company based upon predicted annual sales of �232m. If you are correct this implies that �232 m is the net sales price � ie gross sales price to the wholesalers, although this is not consistent with the company presentation. When I have a moment I will dig out the old Plethora valuation report, which might shed some light.

One things for sure, there certainly is a very wide range - and we will not even get to see the numbers pitched by Rcordati, which according to JG were massively stronger and its impossible to know how the E5 number of �232 has been calculated. I was going to repsond to your admirer, having attracted his attention myself on another share, but knew you would do a better job! He didn't like me pointing out in connection with Summit Therapeutics that Big Pharma were not currently chomping at the bit to get involved in developing new antibiotics and that statistically the likelihood of gaining approval for a DMD drug were sadly very low.

This was announced on 6th March, so the fuel cell should have been received by October 2017. If one follows the announcement, the logical conclusion, in the ansence of any update from Phe is that the AFC fuel cell is not compatible with the Mousetrap. This has implications if true. The anticipated delivery time for the AFC fuel cell is expected to be approximately eight months. Upon delivery of the fuel cell, PowerHouse anticipates having a high quality hydrogen stream (a component of the syngas produced) from the G3-UHt to successfully integrate with the fuel cell, to provide production of electrical power. Receipt of the fuel cell is contingent upon the G3-UHt unit being capable of producing a hydrogen stream compatible with the fuel cell.

Piltick - the 2016 Financials on share options make interesting reading. The quantum of options to KA has risen from 5m to 6m and now 30m ! Options granted in 2014 were at 2.5p and the options in 2016 were granted at a 36% premium to the share price ! I would also like to understand why Phe have agreed to share 50% of the profits with Waste2tricty. What exactly do they bring to the party to command this. Phe shareholders have funded this supposidly groundbreaking globally leading technology- surely Phe holds all the bargaining chips ? On 8 December 2014, PowerHouse Energy Group plc granted 11,000,000 options over ordinary shares to the Board, under the PowerHouse Energy Group plc Unapproved Share Option Plan 2011. The options may be exercised between the Grant date and the tenth anniversary of the Grant date and will lapse if not exercised during that period. The options have an exercise price of 2.5p per share. The options were granted as follows: Mr Keith Allaun � 5,000,000 Mr Brent Fitzpatrick � 3,000,000 Mr James Greenstreet � 3,000,000 On 7 March 2016, PowerHouse Energy Group plc granted 11,000,000 options over ordinary shares to the Board, under the PowerHouse Energy Group plc Unapproved Share Option Plan 2011. The options may be exercised between the Grant date and the fifth anniversary of the Grant date and will lapse if not exercised during that period. The options vested immediately. The fair value of the options granted during the year was determined using the Black Scholes valuation model. The model takes into account a volatility rate of 127.56%, which has been derived from historical experience. A weighted average risk-free interest rate of 2.0% has been applied. The share price was 0.55 pence and the options have an exercise price of 0.75p per share. The options were granted as follows: Mr Keith Allaun � 6,000,000 Mr Brent Fitzpatrick � 5,000,000 Mr James Greenstreet � 4,000,000 These options have incurred a charge of �68,000 in the current year.

He has already p-ssed away 50% of rofits to Waste2tricty- why ? Phe and its shareholders have invested millions in developing the technology- surely if it is so good they hold all the cards ? First we provide an exit for Bond now this, its all beginning to smell very fishy